Heron Therapeutics Inc.

Analysis

Heron Therapeutics Inc. currently manages a company patent portfolio with 1 pending office action. This matter is assigned to a distinct examiner, LANGE, ERIC A. As the busiest examiner for the company, LANGE, ERIC A is responsible for the 1 pending office action that makes up the portfolio's entire active workload.

The portfolio records 0 distinct art units, which may reflect the specific nature or stage of the pending application. With a distinct examiner involved, the company's current patent strategy is focused on a single review process. The pending office action is the only active case currently being prosecuted by the company at the patent office.

Practitioners should focus on the specific requirements and feedback of LANGE, ERIC A to advance the 1 pending office action. The absence of multiple examiners or art units suggests a targeted prosecution profile. Consequently, the resolution of the pending office action is the primary factor in the company's current efforts to secure new patent rights.

The busiest examiner pending count of 1 confirms that the company's immediate patent goals are tied to a single review process. Reviewing the examiner's history can help anticipate potential hurdles and tailor the response. Monitoring the status of the pending office action is vital for timely adjustments to the broader intellectual property strategy.